Why extra GABA activity may cause seizures and memory problems in Down syndrome
Molecular regulators of GABAergic systems that underlie comorbidities in Down syndrome
This research looks at how extra copies of certain genes may raise GABA brain activity and lead to seizures, thinking difficulties, and Alzheimer-like changes in people with Down syndrome.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11124757 on NIH RePORTER |
What this research studies
You will hear about lab work that focuses on genes on chromosome 21, including DSCAM, and how they change inhibitory (GABA) brain connections using cells and animal models tied to human Down syndrome. The team will measure GABA synapses, brain circuit activity, and effects on learning and seizures to find common causes of cognitive problems and epilepsy. They will test whether correcting those GABA changes can reverse circuit and behavioral defects in their models. Although most work is bench-based, the goal is to identify targets that could lead to future therapies for people with Down syndrome.
Who could benefit from this research
Good fit: This work is most relevant to people with Down syndrome, especially those who have seizures, early memory decline, or are at risk for Alzheimer disease.
Not a fit: People without Down syndrome or whose symptoms are due to non-GABA causes are unlikely to benefit directly from this project in the near term.
Why it matters
Potential benefit: If successful, this work could point to new treatment targets to reduce seizures, improve thinking, and delay Alzheimer-related changes in people with Down syndrome.
How similar studies have performed: Prior mouse-model studies have shown that correcting excessive GABA signaling can improve learning and reduce seizures, but translating those findings into human treatments remains unproven.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Ye, Bing — University of Michigan at Ann Arbor
- Study coordinator: Ye, Bing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.